Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia

Leukemia and Lymphoma

Volumn 31, Issue 1-2, 1998, Pages 47-60

  Richardson, Des R ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Cancer; Desferrioxamine; Iron; Iron chelators; Pyridoxal isonicotinoyl hydrazone

Indexed keywords

CHELATING AGENT; DEFEROXAMINE; IRON; PYRIDOXAL ISONICOTINOYLHYDRAZONE;

CELL PROLIFERATION; DNA SYNTHESIS; DRUG COST; HUMAN; INTESTINE ABSORPTION; IRON CHELATION; LEUKEMIA; NEUROBLASTOMA; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR GROWTH;

EID: 0031674853     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809057584     Document Type: Review

References (73)

1. Richardson, D. R. and Ponka, P. (1997). The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta, 1331, 1-40.
2. Ponka, P., Beaumont, C. and Richardson, D. R. (1998). Function and regulation of transferrin and ferritin. Semin. Hematol., 35(1), 35-54.
3. Klausner, R. D., Ashwell, G., van Renswoude, J., Harfbrd, J. B. and Bridges, K. R. (1983). Binding of apotransferrin to K562 cells: Explanation of the transferrin cycle. Proc. Natl Acad. Sci. USA, 80, 2263-2266.
4. Page, M., Baker, E. and Morgan, E. H. (1984). Transferrin and iron uptake by rat hepatocytes in culture. Am. J. Physiol, 246, G26-G33.
5. Trinder, D., Morgan, E. H. and Baker, E. (1986). The mechanism of iron uptake by fetal hepatocytes in culture. Hepatology, 6, 852-858.
6. Richardson, D. R. and Baker, E. (1990). The uptake of iron and transferrin by the human melanoma cell. Biochim. Biophys. Acta, 1053, 1-12.
7. Richardson, D. R. and Baker, E. (1994). Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators and metabolic probes on transferrin and iron uptake. J. Cell. Physiol., 161, 160-168.
8. Trinder, D., Zak, O. and Aisen, P. (1996). Transferrin receptor-independent uptake of diferric transferrin by human hepatoma cells with antisense inhibition of receptor expression. Hepatology, 23, 1512-1520.
9. Fleming, M. D., Trenor, C. C., Su, M. A., Foernzler, S., Beier, D. R., Dietrich, W. F. and Andrews, N. C. (1997). Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nature Genetics, 16, 383-386.
10. Gunshin, H., Mackenzie, B., Berger, U. V., Gunshin, Y., Romero, M. F., Boron, W. F., Nussberger, S., Gollan, J. L. and Hediger, M. A. (1997). Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature, 388, 482-488.
11. Jacobs, A. (1977). Low molecular weight intracellular iron transport compounds. Blood, 50, 433-439.
12. Romslo, I. (1980). Intracellular transport of iron. In: A. Jacobs and M. Worwood (eds.) Iron in Biochemistry and Medicine, Vol. 2, (Academic, London, UK). p. 325.
13. St. Pierre, T., Richardson, D. R., Baker, E. and Webb, J. (1992). A low-spin iron complex in human melanoma and rat hepatoma cells and a high spin iron(II) complex in rat hepatoma cells. Biochim. Biophys. Acta, 1135, 154-158.
14. Breuer, W., Epsztejn, S. and Cabantchik, Z. I. (1995). Iron acquired from transferrin by K562 cells is delivered into a cytoplasmic pool of chelatable iron(II). J. Biol. Chem., 270, 24207-24215.
15. Breuer, W., Epsztejn, S., Millgram, P. and Cabantchik, Z. I. (1995). Transport of iron and other transition metals into cells as revealed by a fluorescent probe. Am. J. Phvsiol., 268, C1354-C1361.
16. Richardson, D. R., Ponka, P. and Vyoral, D. (1996). Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: Examination of the intermediates of iron metabolism. Blood, 87, 3477-3488.
17. Harrison, P. M. and Arosio, P. (1996). The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta, 1275, 161-203.
18. Thelander, L., Gräslund, A. and Thelander, M. (1983). Continual presence of oxygen and iron is required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem. Biophys. Res. Commun., 110, 859-865.
19. Lederman, H. M., Cohen, A., Lee, J. W. W., Freedman, M. H. and Gelfand, E. W. (1984). Deferoxamine: A reversible S phase inhibitor of human lymphocyte proliferation. Blood, 64, 748-753.
20. Fernandez-Pol, J. A. (1977). Iron: Possible cause of the G1 arrest induced in NRK cells by picolinic acid. Biochem. Biophys. Res. Commun., 78, 136-143.
21. 1 phase of the cell cycle. Cancer Res., 53, 3968-3975.
22. Hileti, D., Panayiotidis, P. and Hoffbrand, A. V. (1995). Iron chelators induce apoptosis in proliferating cells. Br. J. Haematol., 89, 181-187.
23. Ul-Haq, R., Wereley, J. P. and Chitambar, C. R. (1995). Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp. Hematol., 23, 428-432.
24. Richardson, D. R. and Milnes, K. (1997). The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood, 89, 3025-3038.
25. Trowbridge, I. S. and Omary, M. B. (1981). Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc. Natl. Acad. Sci. USA. 78, 3039-3043.
26. Sutherland, R., Delia, D., Schneider, C., Newman, R., Kemshead, J. and Greaves, M. (1981). Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc. Natl. Acad. Sci. USA, 78, 4515-519.
27. Weinberg, E. D. (1984). Iron withholding a defense against infection and neoplasia. Physiol. Rev., 64, 65-102.
28. Trowbridge, I. S. and Lopez, F. (1982). Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits tumor cell growth in vitro. Proc. Natl. Acad. Sci. USA. 79, 1175-1179.
29. Hoffbrand, A. V., Ganeshaguru, K., Hooton, J. W. L. and Tattersall, M. H. N. (1976). Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br. J. Haematol., 33, 517-526.
30. Blatt, J. and Stitely, S. (1987). Antineuroblastoma activity of desferrioxamine in human cell lines. Cancer Res., 47, 1749-1750.
31. Bergeron, R. J. and Ingeno, M.J. (1987). Microbial iron chelator-induced cell cycle synchronisation in L1210 cells: potential in combination chemotherapy. Cancer Res., 47, 6010-6016.
32. Estrov, Z., Tawa, A., Wang, X.-H., Dube, I. D., Sulh, H., Cohen, A., Gelfand, E. W. and Freedman, M. H. (1987). In vivo and in vitro effects of desferrioxamine in neonatal acute leukemia. Blood, 69, 757-761.
33. Estrov, Z., Cohen, A., Gelfand, E. W. and Freedman, M. H. (1988). Synergistic antiproliferative effects on HL-60 cells: Deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity. Am. J. Pediatr. Hematol. Oncol., 10, 288-291.
34. Becton, D. L. and Bryles, P. (1988). Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res., 48, 7189-7192.
35. Becton, D. L. and Roberts, B. (1989). Antileukemic effects of desferrioxamine on human myeloid leukemia cell lines. Cancer Res., 49, 4809-4812.
36. Dezza, L., Cazzola, M., Danova, M., Carlo-Stella, C., Bergamaschi, G., Brugnatelli, S., Invernizzi, R., Mazzini, G., Riccardi, A. and Ascari, E. (1989). Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies. Leukemia, 3, 104-107.
37. Donfrancesco, A., Deb, G., Dominici, C., Pileggi, D., Castello, M. A. and Helson, L. (1990). Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res., 50, 4929-4930.
38. Donfrancesco, A., Deb, G., Dominici, C., Angioni, A., Caniglia, M., De Sio, L., Fidani, P., Amici, A. and Helson, L. (1992). Deferoxamine, cyclophosphamide, etoposide, carboplatin. and thiotepa (D-CECat): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am. J. Clin. Oncol, 15, 319-322.
39. Donfrancesco, A., De Bernardi, B., Carli, M., Mancini, A., Nigro, M., De Sio, L., Casale, F., Bagnulo, S., Helson, L. and Deb. G. (1995). Deferoxamine (D) followed by cytoxan (C), etoposide (E), carboplatin (Ca), thio-TEPA (T), induction regimen in advanced neuroblastoma. Eur. J. Cancer, 31A, 612-615.
40. Donfrancesco, A., Deb, G., De Sio, L., Cozza, R. and Castellano, A. (1996). Role of desferrioxamine in tumor therapy. Acta Haematol., 95, 66-69.
41. Ponka, P., Borova, J., Neuwirt, J. and Fuchs, O. (1979). Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett., 97, 317-321.
42. Ponka, P., Borova, J., Neuwirt, J., Fuchs, O. and Necas, E. (1979). A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim. Biophys. Acta, 586, 278-297.
43. Hoy, T., Humphreys, J., Jacobs, A., Williams, A. and Ponka, P. (1979). Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br. J. Haematol., 43, 443-449.
44. Cikrt, M., Ponka, P., Necas, E. and Neuwirt, J. (1980). Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br. J. Haematol., 45, 275-283.
45. Hershko, C., Avramovici-Grisaru, S., Link, G., Gelfand, L. and Sarel, S. (1981). Mechanisms of in vivo chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J. Lab. Clin. Med., 98, 99-108.
46. Williams, A., Hoy, T., Pugh, A. and Jacobs, A. (1982). Pyridoxal complexes as potential chelating agents for oral therapy in transfusional iron overload. J. Pharm. Pharmacol., 34, 730-732.
47. Avramovici-Grisaru, S., Sarel, S., Link, G. and Hershko, C. (1983). Synthesis of iron bis(pyridoxal isonicotinoyl hydrazone) and the in vivo iron-removal properties of some pyridoxal derivatives. J. Med. Chem., 26, 298-302.
48. Kim, B. K., Huebers, H. A. and Finch, C. A. (1987). Effectiveness of oral iron chelators assayed in the rat. Am. J. Hematol., 24, 277-284.
49. Richardson, D. R. and Ponka, P. (1998). Pyridoxal isonicotinoyl hydrazone and its analogues: Potential orally effective iron chelating agents for the treatment of iron overload disease. J. Lab. Clin. Med., (in press).
50. Brittenham, G. M. (1990). Pyridoxal isonicotinoyl hydrazone: an effective iron chelator after oral administration. Semin. Hematol., 27, 112-116.
51. Richardson, D. R., Hefter, G. T., May, P. M., Webb, J. and Baker, E. (1989). Iron chelators of the pyridoxal isonicotinoyl hydrazone class III. Formation constants with calcium(II), magnesium(II), and zinc(II). Biol. Metals, 2, 161-167.
52. Vitolo, L. M. W., Hefter, G. T., Clare, B. W. and Webb J., (1990). Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part 2. Formation constants with iron(III) and iron(II). Inorg. Chim. Acta, 170, 171-176.
53. Richardson, D. R., Wis Vitolo, L. M., Hefter, G. T., May, P. M., Clare, B. W., Webb, J. and Wilairat, P. (1990). Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part I. Ionization characteristics of the ligands and their relevance to biological properties, Inorg. Chim. Acta, 170, 165-170.
54. Edward, J. T., Gauthier, M., Chubb, F. L. and Ponka, P. (1988). Synthesis of new acylhydrazones as iron-chelating compounds. J. Chem. Engin. Data, 33, 538-540.
55. Baker, E., Vitolo, M. L. and Webb, J. M. (1985). Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem. Pharmacol., 34, 3011-3017.
56. Ponka, P., Richardson, D., Baker, E., Schulman, H. M. and Edward, J. T. (1988). Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim. Biaphys. Acta, 967, 122-129.
57. Richardson, D., Baker, E., Ponka, P., Wilairat, P., Vitolo, M. L. and Webb, J. (1988). Effects of pyridoxal isonicotinoyl hydrazone and analogs on iron metabolism in hepatocytes and macrophages in culture. Birth Defects, 23(5B), 81-88.
58. Baker, E., Richardson, D. R., Gross, S. and Ponka, P. (1992). Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology, 15, 492-501.
59. Richardson, D. R. and Ponka, P. (1994). The iron metabolism of the human neuroblastoma cell. Lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J. Lab. Clin. Med., 124, 660-671.
60. Richardson, D. R., Tran, E. and Ponka, P. (1995). The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood, 86, 4295-4306.
61. 59Fe. Biochim. Biophys. Acta, 757, 306-315.
62. Richardson, D. R. (1997). Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process. Biochim. Biophys. Acta, 1320, 45-67.
63. Endicott, J. A. and Ling, V. (1989). The biochemistry of p-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 58, 137-171.
64. Gottesman, M. M. and Pastan, I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427.
65. Böhme, M., Büchler, M., Müller, M. and Keppler, D. (1993). Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Leit., 333, 193-196.
66. Ponka, P., Schulman, H. M. and Wilczynska, A. (1982). Ferric pyridoxal isonicotinoyl hydrazone can provide iron for heme synthesis in reticulocytes. Biochim. Biophys. Acta, 718, 151-158.
67. Chitambar, C. R., Narasimhan, J., Guy, J., Sem, D. S. and O'Brein, W. J. (1991). Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells. Cancer Res., 51, 6199-6201.
68. Seligman, P. A. and Crawford, E. D. (1991). Treatment of advanced transitional cell carcinoma of the bladder with continuous infusion gallium nitrate. J. Natl. Cancer Inst., 83, 1582-1584.
69. Seligman, P. A., Moran, P. L., Schleicher, R. B. and Crawford, E. D. (1992). Treatment with gallium nitrate. Evidence for interference with iron metabolism in vivo. Am. J. Hematol., 41, 232-240.
70. Johnson, D. K., Murphy, T. B., Rose, N. J., Goodwin, W. H. and Pickart, L. (1982). Cytotoxic chelators and chelates 1. Inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper (II) complex of salicylaldehyde benzoyl hydrazone. Inorg. Chim. Acta, 67, 159-165.
71. Kontoghiorghes, G. J., Piga, A. and Hoffbrand, A. V. (1986). Cytotoxic effects of the lipophilic iron chelator omadine. FEBS Lett., 204, 208-212.
72. Richardson, D. R. (1997). Cytotoxic analogues of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: Effect of complexation with copper(II), gallium(III), and iron(III) on their anti-proliferative activity. Antimicrob. Agents Chemother., 41(9), 2061-2063.
73. Singh, S. and Hider, R. C. (1988). Colorimetric detection of the hydroxyl radical: comparison of the hydroxyl radical generating ability of various iron complexes. Anal. Biochem., 171, 47-54.